Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BC3195 |
| Synonyms | |
| Therapy Description |
BC3195 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH3 linked to monomethyl auristatin E (MMAE), which potentially inhibits tumor growth (J Clin Oncol 42, no. 16_suppl (2024) e15008; NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BC3195 | BC-3195|BC 3195 | BC3195 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH3 linked to monomethyl auristatin E (MMAE), which potentially inhibits tumor growth (J Clin Oncol 42, no. 16_suppl (2024) e15008; NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06548672 | Phase I | BC3195 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | Recruiting | USA | 0 |